samedan logo
 
 
 
spacer
home > ebr > summer 2019 > easy as adc
PUBLICATIONS
European Biopharmaceutical Review

Easy as ADC

Designed to deliver cytotoxic agents directly and specifically to diseased cells without damaging healthy tissue, antibodydrug conjugates (ADCs) bring the clinical benefits of improved efficacy and reduced toxicities when compared to conventional medicines and biological therapies. The emergence of fully automated, ultrasensitive, single cell screening technologies has brought new possibilities for the identification of novel antigen targets and ADCs. Such technological advances also offer the promise of greater efficiencies in drug design, development, and manufacture of these complex and costly therapies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Xin Liu has over 15 years of R&D experience in the design and development of various microfluidic devices and systems for cell biology applications. Xin is the Head of Cell and Molecular Biology at Sphere Fluidics and is responsible for managing assay and application development for their flagship product, Cyto-Mine®. Before joining Sphere Fluidics, he spent two years as a post-doctoral Research Associate at the University of Cambridge, UK. Xin gained his PhD in analytical chemistry from the Chinese Academy of Sciences, China.
spacer
Dr Xin Liu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Researcher of the Year - The Americas 2021 winners announced

The winners of the 2021 Clinical Researcher of the Years – The Americas competition have been announced, with the exceptional talent of clinical researchers across the Americas recognised during a live virtual awards ceremony.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement